JANX (Janux Therapeutics, Inc.) Stock Financials & Earnings

JANXJanux Therapeutics, Inc.

Mkt Cap$852M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$18M

Net Income (TTM)-$114M

EPS (TTM)-$1.83

Free Cash Flow (TTM)$0

Gross Margin47.2%

Op. Margin-881.8%

Net Margin-635.5%

FCF Margin0.0%

P/S Ratio (TTM)47.7x

P/E Ratio (TTM)—

YoY Rev Growth+68.9%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$2M	-$14M	-$20M
Q2 23	$1M	-$14M	-$21M
Q3 23	$3M	$2M	-$16M
Q4 23	$2M	$2M	-$16M
Q1 24	$1M	$720K	-$20M
Q2 24	$9M	$8M	-$14M
Q3 24	$439K	$439K	-$36M
Q4 24	$0	$0	-$29M
Q1 25	$0	$0	-$35M
Q2 25	$0	$0	-$45M
Q3 25	$10M	$9M	-$35M
Q4 25	$8M	-$1M	-$42M

Valuation

Operating Cash Flow

Capital Expenditures

CapEx

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q1 23	$16M	$6M	—
Q2 23	$15M	$7M	—
Q3 23	$12M	$6M	—
Q4 23	$12M	$6M	—
Q1 24	$14M	$7M	—
Q2 24	$15M	$8M	—
Q3 24	$19M	$18M	—
Q4 24	$21M	$8M	—
Q1 25	$25M	$10M	—
Q2 25	$35M	$10M	—
Q3 25	$35M	—	$10M
Q4 25	$32M	$11M	—

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$30M	$287M	$317M
Q2 23	$34M	$270M	$303M
Q3 23	$17M	$333M	$350M
Q4 23	$19M	$325M	$344M
Q1 24	$213M	$439M	$652M
Q2 24	$15M	$632M	$646M
Q3 24	$27M	$631M	$658M
Q4 24	$431M	$595M	$1.0B
Q1 25	$74M	$940M	$1.0B
Q2 25	$52M	$944M	$996M
Q3 25	$48M	$941M	$989M
Q4 25	$52M	$914M	$967M

Shares Outstanding

Revenue Per Employee

Revenue / Employee